Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
255.00
-6.08 (-2.33%)
At close: Mar 11, 2026, 4:00 PM EDT
253.60
-1.40 (-0.55%)
After-hours: Mar 11, 2026, 7:55 PM EDT
Krystal Biotech Employees
Krystal Biotech had 295 employees as of December 31, 2025. The number of employees increased by 20 or 7.27% compared to the previous year.
Employees
295
Change (1Y)
20
Growth (1Y)
7.27%
Revenue / Employee
$1,319,085
Profits / Employee
$694,342
Market Cap
7.45B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 295 | 20 | 7.27% | 295 | 0 |
| Dec 31, 2024 | 275 | 46 | 20.09% | 275 | 0 |
| Dec 31, 2023 | 229 | 19 | 9.05% | 229 | 0 |
| Dec 31, 2022 | 210 | 91 | 76.47% | 210 | 0 |
| Dec 31, 2021 | 119 | 44 | 58.67% | 119 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Axsome Therapeutics | 925 |
| Arrowhead Pharmaceuticals | 711 |
| Cytokinetics | 673 |
| Vaxcyte | 507 |
| Halozyme Therapeutics | 423 |
| Kymera Therapeutics | 238 |
| Nuvalent | 228 |
| Arcellx | 209 |
KRYS News
- 22 days ago - Krystal Biotech, Inc. (KRYS) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 22 days ago - Krystal: Profitable Growth And The Expanding Reach Of HSV-1 Technology - Seeking Alpha
- 22 days ago - Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results - GlobeNewsWire
- 4 weeks ago - Krystal Biotech: KB707 Program Bolstered By RMAT And 2nd Half 2026 Update - Seeking Alpha
- 4 weeks ago - Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026 - GlobeNewsWire
- 7 weeks ago - Krystal Biotech: Beyond VYJUVEK Commercialization - Seeking Alpha
- 7 weeks ago - These under-the-radar stocks combine fast growth with big upside potential - Market Watch
- 2 months ago - Krystal Biotech, Inc. (KRYS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha